SciClone Pharmaceuticals, Inc.  

(Public, NASDAQ:SCLN)   Watch this stock  
Find more results for SCLN
-0.07 (-0.68%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.23 - 10.56
52 week 6.47 - 15.02
Open 10.43
Vol / Avg. 0.00/464,282.00
Mkt cap 510.59M
P/E 18.95
Div/yield     -
EPS 0.54
Shares 49.91M
Beta 1.80
Inst. own 82%
Aug 9, 2016
Q2 2016 SciClone Pharmaceuticals Inc Earnings Release Add to calendar
Jun 10, 2016
SciClone Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 9, 2016
SciClone Pharmaceuticals Inc Annual Shareholders Meeting
May 10, 2016
Q1 2016 SciClone Pharmaceuticals Inc Earnings Release
May 10, 2016
Q1 2016 SciClone Pharmaceuticals Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 21.55% 18.74%
Operating margin 25.82% 19.02%
EBITD margin - 19.61%
Return on average assets 14.78% 14.79%
Return on average equity 17.09% 17.59%
Employees 590 -
CDP Score - -


950 Tower Ln Ste 900
FOSTER CITY, CA 94404-2125
United States - Map
+1-650-3583456 (Phone)
+1-650-3583469 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in approximately 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, the Company markets approximately seven partnered and in-licensed products in China. The Company's development portfolio includes Angiomax, Neucardin, Loramyc, Cleviprex, RapidFilm, VIBATIV and SGX942. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Officers and directors

Jon S Saxe Independent Chairman of the Board
Age: 79
Bio & Compensation  - Reuters
Friedhelm Blobel Ph.D. President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Wilson W. Cheung Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 46
Bio & Compensation  - Reuters
Hong Zhao Chief Executive Officer - China Operations
Age: 51
Bio & Compensation  - Reuters
Robert S. King Ph.D. Senior Vice President - Product Development and Supply Chain
Age: 48
Bio & Compensation  - Reuters
Raymond A Low CPA Vice President - Finance, Controller
Age: 58
Bio & Compensation  - Reuters
Charles Meng Vice President - Compliance, General Counsel
Age: 52
Bio & Compensation  - Reuters
Lan Xie CPA Vice President - Finance, China Chief Financial Officer
Age: 42
Bio & Compensation  - Reuters
Nancy T. Chang Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 66
Bio & Compensation  - Reuters